###begin article-title 0
###xml 31 36 31 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 38 44 38 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 48 54 48 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PALB2 </italic>
Analysis of large deletions in BRCA1, BRCA2 and PALB2 genes in Finnish breast and ovarian cancer families
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 10 16 10 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 129 135 129 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PALB2 </italic>
BRCA1 and BRCA2 are the two most important genes associated with familial breast and ovarian cancer susceptibility. In addition, PALB2 has recently been identified as a breast cancer susceptibility gene in several populations. Here we have evaluated whether large genomic rearrangement in these genes could explain some of Finnish breast and/or ovarian cancer families.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 223 228 223 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 230 236 230 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 240 245 240 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PALB2</italic>
###xml 20 28 <span type="species:ncbi:9606">patients</span>
Altogether 61 index patients of Northern Finnish breast and/or ovarian cancer families were analyzed by Multiplex ligation-dependent probe amplification (MLPA) method in order to identify exon deletions and duplications in BRCA1, BRCA2 and PALB2. The families have been comprehensively screened for germline mutation in these genes by conventional methods of mutation analysis and were found negative.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 36 41 36 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 202 208 202 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 211 216 211 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PALB2</italic>
We identified one large deletion in BRCA1, deleting the most part of the gene (exon 1A-13) in one family with family history of ovarian cancer. No large genomic rearrangements were identified in either BRCA2 or PALB2.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 31 37 31 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 40 46 40 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 161 166 161 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 215 221 215 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PALB2 </italic>
###xml 12 17 <span type="species:ncbi:9606">women</span>
In Finland, women eligible for BRCA1 or BRCA2 mutation screening, when found negative, could benefit from screening for large genomic rearrangements at least in BRCA1. On the contrary, the genomic rearrangements in PALB2 seem not to contribute to the hereditary breast cancer susceptibility.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 68 74 68 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 78 84 78 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 328 329 328 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 330 331 330 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 372 378 372 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 382 388 382 388 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 555 556 555 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 557 558 557 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 716 717 716 717 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 718 719 718 719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 740 746 740 746 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 750 756 750 756 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 61 66 <span type="species:ncbi:9606">women</span>
Breast cancer is the most frequently occurring malignancy in women. BRCA1 and BRCA2 are the two major susceptibility genes, accounting for varying fraction of familial breast and ovarian cancer cases in different populations. In Finland, mutations in these genes explain approximately 20% of breast and ovarian cancer families [1,2]. Most of the alterations identified in BRCA1 and BRCA2 are point mutations and small insertions/deletions, but increasing number of large genomic rearrangements in both genes have been identified in different populations [3-6]. Rearrangements have been described throughout the genes, and majority of them are unique and introduce a premature termination codon in the reading frame [3,6]. The proportion of BRCA1 and BRCA2 mutations due to genomic rearrangements is not expected to vary markedly in different populations, although there might be accumulation of certain mutations due to a founder effect.
###end p 11
###begin p 12
###xml 103 109 103 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 112 118 112 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 119 120 119 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 121 122 121 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 268 269 268 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 333 334 333 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 412 413 412 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 543 548 543 548 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 550 555 550 555 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 557 561 557 561 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATM </italic>
###xml 565 571 565 571 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD50 </italic>
###xml 582 583 582 583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 584 586 584 586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 587 589 587 589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 725 728 725 728 <sup xmlns:xlink="http://www.w3.org/1999/xlink">th </sup>
###xml 764 767 764 767 <sup xmlns:xlink="http://www.w3.org/1999/xlink">th </sup>
###xml 935 936 935 936 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 985 991 985 991 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 995 1001 995 1001 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
Previous studies performed in the Finnish population have not observed large genomic rearrangements in BRCA1 or BRCA2 [7-9]. However, in the previous studies either the method used (Southern blotting analysis on part of these genes) has not allowed sensitive testing [7], the study has concentrated only on male breast cancer cases [9] or the analyzed samples were derived from a geographically restricted area [8]. In Finland, the difference in geographical distribution has been reported for several cancer susceptibility alleles, including BRCA1, BRCA2, ATM and RAD50 mutations [2,10-12], which is the result of strong founder effect and population history. The settlement was restricted to the coastal areas during the 15th century, and it was not until the 17th century that the vast inland regions were gradually inhabited by a relatively small number of individuals, resulting in several regionally occurring founder mutations [2]. Consequently, large genomic rearrangements in BRCA1 and BRCA2 might still be at least partly responsible for the hereditary predisposition to breast and ovarian cancer in Finland.
###end p 12
###begin p 13
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PALB2 </italic>
###xml 70 72 70 72 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 73 75 73 75 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 144 146 144 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 147 149 147 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 152 158 152 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PALB2 </italic>
###xml 299 301 299 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 357 363 357 363 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PALB2 </italic>
###xml 457 463 457 463 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PALB2 </italic>
###xml 522 528 522 528 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PALB2 </italic>
###xml 585 587 585 587 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 588 590 588 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 664 670 664 670 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PALB2 </italic>
PALB2 was recently identified as a breast cancer susceptibility gene [13,14] and mutations in it have since been reported in other populations [15-17]. PALB2 encodes a protein that binds to BRCA2 and this interaction is crucial for certain BRCA2 DNA damage response and tumor suppression functions [18]. The breast cancer associated mutations identified in PALB2 are expected to be deleterious, and all result in protein truncations. The risk estimates for PALB2 mutations have ranged from two- to fourfold, although some PALB2 mutations have been suggested to have higher penetrance [13-15]. Here, we wanted to investigate whether large genomic rearrangements in PALB2 could also explain some of the Finnish breast and/or ovarian cancer families.
###end p 13
###begin p 14
###xml 150 155 150 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 157 163 157 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 167 173 167 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PALB2 </italic>
###xml 274 276 274 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 433 434 433 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 435 437 435 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
In the current study we have used Multiplex ligation-dependent probe amplification (MLPA) in order to identify exon deletions and duplications in the BRCA1, BRCA2 and PALB2 genes. MLPA has been proven to be very useful in detecting copy number changes in genomic sequences [19]. The families selected to this study have been comprehensively screened for germline mutation in these genes by conventional methods of mutation analysis [2,13] and were found negative.
###end p 14
###begin title 15
Methods
###end title 15
###begin title 16
Breast and/or ovarian cancer families
###end title 16
###begin p 17
###xml 176 181 176 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 183 189 183 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 193 199 193 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PALB2 </italic>
###xml 224 225 224 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 226 228 226 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 20 28 <span type="species:ncbi:9606">patients</span>
###xml 867 874 <span type="species:ncbi:9606">patient</span>
###xml 1122 1130 <span type="species:ncbi:9606">patients</span>
Altogether 61 index patients of Northern Finnish breast and/or ovarian cancer families were selected for the study. These families have been screened for germline mutations in BRCA1, BRCA2 and PALB2 and were found negative [2,13]. 41 of the families had three or more cases of breast and/or ovarian cancer in first- or second-degree relatives, and 11 families had two cases of breast and/or ovarian cancer in first- or second-degree relatives, of which at least one with early disease onset (</= 35 years), bilateral disease or multiple primary tumors. Four families had one case of breast and ovarian cancer each, three families had two breast cancer cases, of which one diagnosed at young age </= 43 years, and two families showed one breast cancer case (</= 40 years) with multiple primary tumors. The affected index cases of these families were analyzed, and the patient with youngest age at diagnosis or the one with multiple tumors was selected as an index. The study has been approved by the Ethical Board of the Northern Ostrobothnia Health Care District and the Finnish Ministry of Social Affairs and Health. All patients provided informed consent to participate in this study.
###end p 17
###begin title 18
MLPA and data analysis
###end title 18
###begin p 19
###xml 24 30 24 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 87 93 87 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 105 111 105 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PALB2 </italic>
###xml 298 300 298 300 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 432 438 432 438 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 506 512 506 512 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 667 673 667 673 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PALB2 </italic>
The SALSA MLPA kits for BRCA1 (primary screening kit P002B and confirmation kit P087), BRCA2 (P045B) and PALB2 (P057) kits (MRC-Holland, Netherlands) were used according to the manufacturer's instructions. After PCR amplification with IRD800 labeled primers the samples were analyzed with Li-Cor IR2 4200-S DNA Analysis system (Li-Cor Inc., Lincoln, NE) and Gene Profiler 4.05 analysis program (Scanalytics, Inc., Fairfax, VA). For BRCA1 analysis the used deletion control had deletions in exons 1A-2, for BRCA2 analysis the control sample showed constant 50% reduction in band intensity resulting from a SNP locating three base pairs from the ligation site, and for PALB2 analysis the used control had heterozygous deletions in exons 1-3 and 5-10 in addition to homozygous deletion of exon 4.
###end p 19
###begin p 20
The information regarding the integrated density of each band received from GeneProfiler was analyzed by MLPA spreadsheets (National Genetics Reference Laboratory) in Excel Software according to the instructions. Dosage quotients 0.35-0.65 were considered deleted and dosage quotients 1.35-1.65 duplicated, and samples with quality value (standard deviation of the control ligation products) exceeding 0.1 were rejected. For the DNA sample positive for a genomic rearrangement, analysis was repeated using an independent sample in an independent assay.
###end p 20
###begin title 21
Results
###end title 21
###begin p 22
###xml 82 87 82 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 89 95 89 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 99 105 99 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PALB2 </italic>
###xml 123 129 123 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 133 139 133 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PALB2 </italic>
###xml 230 236 230 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 257 258 257 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 433 439 433 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 666 667 666 667 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 37 45 <span type="species:ncbi:9606">patients</span>
###xml 466 473 <span type="species:ncbi:9606">patient</span>
We have analyzed a total of 61 index patients for large genomic rearrangements in BRCA1, BRCA2 and PALB2 genes by MLPA. In BRCA2 and PALB2 no deletions or duplications were observed. We did, however, observe one large deletion in BRCA1 (exon 1A-13) (Figure 1), deleting the most part of the gene, including the promoter region. This deletion spans over 43 kb. The initial observation with P002B kit was subsequently confirmed by the BRCA1 confirmation kit P087. The patient carrying the deletion allele was diagnosed with ovarian cancer at the age of 49 years. The family had strong history of cancer, and there were altogether three cases of ovarian cancer (Figure 2). DNA was not available for testing from any other family members.
###end p 22
###begin p 23
###xml 0 65 0 65 <bold xmlns:xlink="http://www.w3.org/1999/xlink">MLPA analysis of a patient with family history of ovarian cancer.</bold>
###xml 112 118 112 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 203 209 203 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 19 26 <span type="species:ncbi:9606">patient</span>
MLPA analysis of a patient with family history of ovarian cancer. A large genomic deletion of exons 1A to 13 in BRCA1 was found. Y-axis dosage quotients, X-axis used control probes (blue) and individual BRCA1 exons (green).
###end p 23
###begin p 24
###xml 41 46 41 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 0 47 0 47 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Family exhibiting exon 1A-13 deletion in <italic>BRCA1</italic>.</bold>
Family exhibiting exon 1A-13 deletion in BRCA1. Index case is shown with an arrow.
###end p 24
###begin title 25
Discussion
###end title 25
###begin p 26
###xml 22 28 22 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 32 38 32 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 102 104 102 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 120 126 120 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PALB2 </italic>
###xml 303 305 303 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 306 308 306 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 320 326 320 326 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 330 336 330 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 439 440 439 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 441 442 441 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 723 729 723 729 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 733 739 733 739 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 800 806 800 806 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PALB2 </italic>
###xml 586 594 <span type="species:ncbi:9606">patients</span>
###xml 769 776 <span type="species:ncbi:9606">patient</span>
Germline mutations in BRCA1 and BRCA2 cause an increased lifetime risk for breast and ovarian cancer [20]. In addition, PALB2 has recently been identified as a breast cancer susceptibility gene in several populations, but its association with increased risk for ovarian cancer has not been established [13-17]. Although BRCA1 and BRCA2 rearrangements have previously been studied in the Finnish population, none have so far been reported [7-9]. The earlier studies have, however, been concentrating on families deriving from geographically restricted area or only on male breast cancer patients, or have used the less sensitive Southern blotting method. Therefore, a comprehensive analysis of genomic rearrangements in the BRCA1 and BRCA2 genes in the Northern Finnish patient cohort was needed. For PALB2 this is the first study designed to detect large genomic rearrangements in the Finnish population.
###end p 26
###begin p 27
###xml 167 172 167 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 245 247 245 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 290 295 290 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 434 440 434 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 462 464 462 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 493 499 493 499 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 629 631 629 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 632 634 632 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 746 752 746 752 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 319 326 <span type="species:ncbi:9606">patient</span>
The index cases of 61 families included in this study were analyzed for rearrangements in the three genes by MLPA, and in one family we identified a large deletion in BRCA1. The observed deletion removes most of the gene including the promoter [21], thereby preventing the transcription of BRCA1. The mutation positive patient displayed a family history of ovarian cancer, which has been shown to increase the likelihood of finding a BRCA1 mutation in a family [22]. Deletions that remove the BRCA1 promoter have previously been described, but the earlier studies have not associated these changes with any particular phenotype [23-26]. Our result provide the first evidence that, like in many other studied populations, large genomic changes in BRCA1 do also exist in Finland. However, these mutations seem to be rare, if not unique, as this deletion was seen in only one out of 61 families.
###end p 27
###begin p 28
###xml 30 36 30 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 223 224 223 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 225 226 225 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 227 229 227 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 286 287 286 287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 300 306 300 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 438 444 438 444 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 601 607 601 607 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 610 616 610 616 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 732 737 732 737 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 811 817 811 817 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 582 587 <span type="species:ncbi:9606">women</span>
To date, only three different BRCA1 mutations have been identified in Northern Finnish breast and/or ovarian cancer families. Two of these mutations, 3745delT and 4216-2ntA>G, represent recurrent Finnish founder mutations [1,2,27], accounting for three mutation positive families each [2]. The third BRCA1 mutation is the currently identified large deletion of exons 1A-13, which represents 14.3% (1/7) of the identified Northern Finnish BRCA1 positive families. Even though the deletion allele was observed only in one out 61 currently analyzed families, our results suggests that women eligible for BRCA1 or BRCA2 mutation screening, when found negative, could benefit from screening for large genomic rearrangements, at least in BRCA1. Additional work is still needed in order to determine the prevalence of BRCA2 rearrangements in Finland, as the current study was based only on relatively small number of families.
###end p 28
###begin p 29
###xml 60 65 60 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 147 153 147 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 157 163 157 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 325 331 325 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 335 341 335 341 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 360 361 360 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 362 363 362 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 364 365 364 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 366 367 366 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 368 370 368 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 414 420 414 420 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PALB2 </italic>
###xml 529 535 529 535 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PALB2 </italic>
###xml 601 603 601 603 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 690 696 690 696 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PALB2 </italic>
###xml 763 765 763 765 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
Despite the identification of one large genomic deletion in BRCA1, our results support the previous conclusions that the genomic rearrangements in BRCA1 and BRCA2 are not a major cause for increased breast cancer susceptibility in Finland, and that the previously reported Finnish founder mutations represent the majority of BRCA1 and BRCA2 positive families [1,2,7-9,27]. No exon deletions or duplications of the PALB2 gene were identified in the studied index cases of 61 families. This suggests that genomic rearrangements in PALB2 are very rare, which has also been indicated by a previous study [16]. At least in the Finnish population the major breast cancer associated aberration in PALB2 appears to be the previously reported founder truncation mutation [13].
###end p 29
###begin title 30
Conclusion
###end title 30
###begin p 31
###xml 31 37 31 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 40 46 40 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 161 166 161 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 211 217 211 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PALB2 </italic>
###xml 12 17 <span type="species:ncbi:9606">women</span>
In Finland, women eligible for BRCA1 or BRCA2 mutation screening, when found negative, could benefit from screening for large genomic rearrangements at least in BRCA1. In contrast, the genomic rearrangements in PALB2 seem not to contribute to the hereditary breast cancer susceptibility in Finland.
###end p 31
###begin title 32
Competing interests
###end title 32
###begin p 33
The authors declare that they have no competing interests.
###end p 33
###begin title 34
Authors' contributions
###end title 34
###begin p 35
KP carried out the MLPA and data analysis, and drafted the manuscript. HE, JN and SS helped to draft the manuscript. RW participated in study design and in drafting the manuscript. All authors read and approved the final manuscript.
###end p 35
###begin title 36
Pre-publication history
###end title 36
###begin p 37
The pre-publication history for this paper can be accessed here:
###end p 37
###begin p 38

###end p 38
###begin title 39
Acknowledgements
###end title 39
###begin p 40
###xml 102 108 102 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PALB2 </italic>
###xml 246 253 <span type="species:ncbi:9606">patient</span>
We thank Dr Andrew Wallace for providing us the Excel MLPA spreadsheets and Dr Johan P. de Winter for PALB2 deletion control. We thank Drs Guillermo Blanco, Ulla Puistola, Aki Mustonen and Jaakko Ignatius, and Nurse Outi Kajula for their help in patient contacts. This study was financially supported by Orion-Farmos Research Foundation, Cancer Foundation of Northern Finland, Academy of Finland, Finnish Cancer Society, Sigrid Juselius Foundation, Finnish Cultural Foundation and Maud Kuistila Memorial Foundation.
###end p 40
###begin article-title 41
Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes
###end article-title 41
###begin article-title 42
Evidence of founder mutations in Finnish BRCA1 and BRCA2 families
###end article-title 42
###begin article-title 43
Genomic rearrangements in the BRCA1 and BRCA2 genes
###end article-title 43
###begin article-title 44
Large genomic deletions inactivate the BRCA2 gene in breast cancer families
###end article-title 44
###begin article-title 45
Large genomic rearrangements of both BRCA2 and BRCA1 are a feature of the inherited breast/ovarian cancer phenotype in selected families
###end article-title 45
###begin article-title 46
The contribution of germline rearrangements to the spectrum of BRCA2 mutations
###end article-title 46
###begin article-title 47
Exclusion of large deletions and other rearrangements in BRCA1 and BRCA2 in Finnish breast and ovarian cancer families
###end article-title 47
###begin article-title 48
Search for large genomic alterations of the BRCA1 gene in a Finnish population
###end article-title 48
###begin article-title 49
Large genomic BRCA2 rearrangements and male breast cancer
###end article-title 49
###begin article-title 50
Multiple founder effects and geographical clustering of BRCA1 and BRCA2 families in Finland
###end article-title 50
###begin article-title 51
RAD50 and NBS1 are Breast Cancer Susceptibility Genes Associated with Genomic Instability
###end article-title 51
###begin article-title 52
Evaluation of the role of Finnish ataxia-telangiectasia mutations in hereditary predisposition to breast cancer
###end article-title 52
###begin article-title 53
A recurrent mutation in PALB2 in Finnish cancer families
###end article-title 53
###begin article-title 54
PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene
###end article-title 54
###begin article-title 55
Analysis of PALB2/FANCN-associated breast cancer families
###end article-title 55
###begin article-title 56
###xml 133 138 <span type="species:ncbi:9606">women</span>
Identification of a novel truncating PALB2 mutation and analysis of its contribution to early-onset breast cancer in French-Canadian women
###end article-title 56
###begin article-title 57
Analysis of FANCB and FANCN/PALB2 Fanconi Anemia genes in BRCA1/2-negative Spanish breast cancer families
###end article-title 57
###begin article-title 58
Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2
###end article-title 58
###begin article-title 59
MLPA and MAPH: new techniques for detection of gene deletions
###end article-title 59
###begin article-title 60
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies
###end article-title 60
###begin article-title 61
Complex regulation of the BRCA1 gene
###end article-title 61
###begin article-title 62
A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families
###end article-title 62
###begin article-title 63
Identification of a 14 kb deletion involving the promoter region of BRCA1 in a breast cancer family
###end article-title 63
###begin article-title 64
Distinct BRCA1 rearrangements involving the BRCA1 pseudogene suggest the existence of a recombination hot spot
###end article-title 64
###begin article-title 65
Characterisation of a 161 kb deletion extending from the NBR1 to the BRCA1 genes in a French breast-ovarian cancer family
###end article-title 65
###begin article-title 66
Genomic rearrangements account for more than one-third of the BRCA1 mutations in northern Italian breast/ovarian cancer families
###end article-title 66
###begin article-title 67
Screening for BRCA1 and BRCA2 mutations in Eastern Finnish breast/ovarian cancer families
###end article-title 67

